Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab

Clinical Cancer Research

Volumn 14, Issue 22, 2008, Pages 7554-7563

  Schultheis, Anne M ^a   Lurje, Georg ^a   Rhodes, Katrin E ^a   Zhang, Wu ^a   Yang, Dongyun ^a   Garcia, Agustin A ^a   Morgan, Robert ^b   Gandara, David ^c   Scudder, Sidney ^c   Oza, Amit ^d   Hirte, Hal ^d   Fleming, Gini ^e   Roman, Lynda ^a   Lenz, Heinz Josef ^a,f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY OF CHICAGO   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CHEMOKINE RECEPTOR CXCR2; CYCLOPHOSPHAMIDE; GENOMIC DNA; INTERLEUKIN 8; VASCULOTROPIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ALLELE; ARTICLE; CANCER RECURRENCE; CLINICAL TRIAL; DNA POLYMORPHISM; GENOTYPE; HUMAN; METASTASIS; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; DISEASE FREE SURVIVAL; DRUG RESISTANCE; FEMALE; GENETICS; KAPLAN MEIER METHOD; MORTALITY; MULTICENTER STUDY; OVARY TUMOR; PILOT STUDY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; OVARIAN NEOPLASMS; PILOT PROJECTS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 58149346076     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0351     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol 2006;107:1399-410.
3. Mor G, Visintin I, Lai Y, et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 2005;102:7677-82.
4. Rustin GJ, Quinn M, Thigpen T, et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004;96:487-8.
5. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27.
6. Abulafia O, Triest WE, Sherer DM. Angiogenesis in primary and metastatic epithelial ovarian carcinoma. Am J Obstet Gynecol 1997;177:541-7.
7. Bamberger ES, Perrett CW. Angiogenesis in epithelian ovarian cancer. Mol Pathol 2002;55:348-59.
8. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.
9. Wong C, Wellman TL, Lounsbury KM. VEGF and HIF-1α expression are increased in advanced stages of epithelial ovarian cancer. Gynecol Oncol 2003;91:513-7.
10. Horiuchi A, Imai T, Shimizu M, et al. Hypoxia-induced changes in the expression of VEGF, HIF-1α and cell cycle-related molecules in ovarian cancer cells. Anticancer Res 2002;22:2697-702.
11. Tanimoto K, Yoshiga K, Eguchi H, et al. Hypoxia-inducible factor-1α polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 2003;24:1779-83.
12. Nagy JA, Masse EM, Herzberg KT, et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 1995;55:360-8.
13. Nagy JA, Meyers MS, Masse EM, Herzberg KT, Dvorak HF. Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity. Cancer Res 1995;55:369-75.
14. Rasila KK, Burger RA, Smith H, Lee FC, Verschraegen C. Angiogenesis in gynecological oncology mechanism of tumor progression and therapeutic targets. Int J Gynecol Cancer 2005;15:710-26.
15. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36.
16. Caponigro F, Basile M, de Rosa V, Normanno N. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004. Anticancer Drugs 2005;16:211-21.
17. Venkatakrishnan G, Salgia R, Groopman JE. Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem 2000;275:6868-75.
18. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008;26:76-82.
19. Hull J, Thomson A, Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 2000;55:1023-7.
20. Gordon MA, Gil J, Lu B, et al. Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics 2006;7:67-88.
21. Lurje G, Zhang W, Schultheis AM, et al. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol 2008;19:1734-41.
22. Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 2006;42:768-78.
23. Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003;170:3369-76.
24. Strieter RM. Masters of angiogenesis. Nat Med 2005;11:925-7.
25. Mizukami Y, Jo WS, Duerr EM, et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1á-deficient colon cancer cells. Nat Med 2005;11:992-7.
26. Renzoni E, Lympany P, Sestini P, et al. Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum 2000;43:1633-40.
27. Martinez A. A new family of angiogenic factors. Cancer Lett 2006;236:157-63.
28. Nikitenko LL, Fox SB, Kehoe S, Rees MC, Bicknell R. Adrenomedullin and tumour angiogenesis. Br J Cancer 2006;94:1-7.
29. Nikitenko LL, MacKenzie IZ, Rees MC, Bicknell R. Adrenomedullin is an autocrine regulator of endothelial growth in human endometrium. Mol Hum Reprod 2000;6:811-9.
30. Nagaya N, Mori H, Murakami S, Kangawa K, Kitamura S. Adrenomedullin: angiogenesis and gene therapy. Am J Physiol Regul Integr Comp Physiol 2005;288:R1432-7.
31. Ribatti D, Nico B, Spinazzi R, Vacca A, Nussdorfer GG. The role of adrenomedullin in angiogenesis. Peptides 2005;26:1670-5.
32. Ishimitsu T, Hosoya K, Tsukada K, et al. Microsatellite DNA polymorphism of human adrenomedullin gene in normotensive subjects and patients with essential hypertension. Hypertension 2001;38:9-12.
33. Ishimitsu T, Tsukada K, Minami J, et al. Microsatellite DNA polymorphism of human adrenomedullin gene in type 2 diabetic patients with renal failure. Kidney Int 2003;63:2230-5.
34. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-80.
35. Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001;98:1904-13.
36. Balasubramanian SP, Brown NJ, Reed MW. Role of genetic polymorphisms in tumour angiogenesis. Br J Cancer 2002;87:1057-65.
37. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000;37:443-8.
38. Polterauer S, Grimm C, Mustea A, et al. Vascular endothelial growth factor gene polymorphisms in ovarian cancer. Gynecol Oncol 2007;105:385-9.
39. Krippl P, Langsenlehner U, Renner W, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 2003;106:468-71.
40. Heist RS, Zhai R, Liu G, et al. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol 2008;26:856-62.
41. Kim JG, Sohn SK, Chae YS, et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol 2007;18:1030-6.